Picture EBD Group World of Partnering Opportunities 650x100px
Document › Details

Pharnext S.A.. (2/7/17). "Press Release: Pharnext to Present at 2017 BIO CEO & Investor Conference". Paris.

Region Region New York, NY
  Country United States (USA)
Organisations Organisation Pharnext S.A. (Euronext Paris: ALPHA)
  Organisation 2 BIO (US) (Biotechnology Innovation Organization, formerly Biotechnology Industry Organization)
Products Product BIO CEO & Investor Conference 2017 New York
  Product 2 PXT-3003 (Pharnext)
Index terms Index term Pharnext–BIO (US): investor conference, 201702 supply service Pharnext SA presents at BIO CEO & Investor Conference NY
  Index term 2 Pharnext–Stern IR: public relations, 201701 service existent US Investor Relations by Stern IR
Person Person McCabe, Sarah (Stern Investor Relations 201701)

Pharnext SA (FR00111911287 - ALPHA), a French biopharmaceutical company developing an advanced portfolio of products in the field of neurodegenerative diseases, announced today that company management will present a corporate overview at the 2017 BIO CEO & Investor Conference.

The presentation will take place as follows:
> Date: Monday, February 13th, 2017
> Time: 10:00 am ET (4:00 pm CET)
> Venue: The Waldorf Astoria in New York, New York.

If you are interested in meeting the Pharnext management team during this event, please send an email to Sarah McCabe at

About Pharnext

Pharnext is an advanced clinical stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext focuses on neurodegenerative diseases and has two lead products in clinical development: PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY™. The company identifies and develops synergic combinations of repositioned drugs at low dose. These PLEODRUG™ offer several key advantages: efficacy, safety, and intellectual property including several composition of matter patents already granted. The Company is supported by a world-class scientific team.

The company Pharnext is listed on Euronext Alternext Stock Exchange in Paris (ISIN code: FR00111911287).

For more information, visit

Record changed: 2023-06-05


Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Pharnext S.A. (Euronext Paris: ALPHA)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Berlin Partner BIO 2024 International Convention San Diego 650x300px

» top